NEURACAP
Sector OutlookPublished · 23 pages · Free to read

Surgical and Orthopedic Devices Sector Outlook — September 2026

A sector outlook on surgical and orthopedic devices for investors and operators, covering business-model segmentation, EV/Revenue valuation across the approved company set, precedent transaction patterns and the strategic implications of procedure economics and recurring revenue.

For information only. Not an appraisal or a fairness opinion.

What moved since: Surgical and Orthopedic Devices M&A update, 14–28 September 2026

Key figures

Sector median valuation
2.3x
EV / Revenue, CY2027E
Premium end of the range
6.6x
Highest-priced rated company
Discount end of the range
1.0x
Lowest-priced rated company
Instruments & consumables median
6.8x
vs 2.2x for diversified platforms

Read the report

NeuraCap

HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES

Surgical and Orthopedic Devices: Premiums Follow Growth

The report shows where public-market premiums sit, how business models differ and what precedent transactions suggest buyers value.

September 2026 · Prepared by NeuraCap AI · Confidential

Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E)

Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice

1

1 / 23

Executive summary

Surgical and orthopedic device valuations diverge sharply across business models: faster-growing, recurring-procedure franchises trade well above diversified implant and device platforms, with forward EV/Revenue multiples spanning 6.6x to 1.0x against a 2.3x sector median. Instruments and consumables businesses command the highest pricing at 6.8x, well above the 2.2x seen in diversified platforms, while balanced growth-and-margin performance remains uncommon. Precedent transactions point the same way, with buyers favouring procedure breadth and channel fit.

Key findings

  • Faster-growing names price above slower-growing peers, 2.8x vs 2.1x.
  • Forward multiples span 6.6x to 1.0x, showing buyers value durability.
  • Instruments and consumables command 6.8x versus 2.2x for diversified platforms.
  • Balanced growth and margin remain rare: only 3 of 16 covered names clear both.

What each page shows

The analyst’s walkthrough of the deck, page by page.

  1. 01

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES

    Cover slide introducing the Surgical and Orthopedic Devices sector outlook dated September 2026.

    We're opening our Surgical and Orthopedic Devices sector outlook, built on market data as of September 28, 2026. Premiums follow growth here, and by the end of this deck you'll see exactly where — and why that matters for how you think about this space.

    Everything on this page

    HEALTH CARE › HEALTH CARE EQUIPMENT AND SERVICES › SURGICAL AND ORTHOPEDIC DEVICES Surgical and Orthopedic Devices: Premiums Follow Growth The report shows where public-market premiums sit, how business models differ and what precedent transactions suggest buyers value. September 2026 · Prepared by NeuraCap AI · Confidential Market data as of 2026-09-28 · primary valuation basis EV / Revenue (CY2027E) Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 1

  2. 02
    CONTENTS

    What This Report Covers

    Contents page listing the five report sections plus the appendix.

    We've structured this report so the bottom line comes first — read section one alone and you still have the full argument. From there we walk through the landscape, valuation and situations, precedent transactions and the strategic implications, with full comparables in the appendix for anyone who wants to trace a number.

    Everything on this page

    CONTENTS What This Report Covers 01 The Bottom Line Growth, Recurring Pull-Through and Procedure Breadth Separate the Field 02 The Landscape Four Operating Models Compete for Capital on Different Terms 03 Valuation & Situations The Premium End Combines Faster Growth with Durable Procedure Economics 04 Precedent Transactions Strategic Buyers Keep Adding Procedure Breadth and Channel Reach 05 Strategic Implications The Operating Agenda Is to Deepen Pull-Through and Protect Growth Quality 06 Appendix Comparables Detail, Methodology, Sources and Assumptions Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 2

  3. 03
    01 · THE BOTTOM LINE

    Surgical and Orthopedic Devices Split Across Four Models, with Growth and Instruments Priced Higher

    This page summarizes the report's core finding: surgical and orthopedic devices split across four operating models, with growth and instruments segments priced higher.

    The market splits this sector into four operating models, and it prices them very differently. Faster-growing names sit at a 2.8x median versus 2.1x for slower-growing peers, and the forward range runs from 6.6x at the premium end down to 1.0x at the discount end even after expected growth is priced in. Instruments and consumables businesses command 6.8x versus 2.2x for diversified implant and device platforms, and among names with margin data only a handful clear both the growth and margin bar. So what: recurring procedure economics, not scale alone, is what the market is paying up for.

    Everything on this page

    01 · THE BOTTOM LINE Surgical and Orthopedic Devices Split Across Four Models, with Growth and Instruments Priced Higher The full story on one page · figures on EV / Revenue (CY2027E), market data as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (25 of 27 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (26 of 27 companies), so this report follows it. Qualitative characterisations are NeuraCap views. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 3 1 Faster-Growing Names Sit Above Slower-Growing Names The 13 names above the growth split are associated with higher forward revenue pricing than the 12 names below it. Their middle sits at 2.8x versus 2.1x, alongside stronger expected growth. 2 The Forward Premium Spans a Wide Range The premium end sits at 6.6x, compared with 1.0x at the discount end. These are forward multiples, so the gap persists after forecast growth is already reflected and suggests buyers distinguish durability. 3 Instruments and Consumables Lead Diversified Platforms Surgical instruments and procedural consumables sit at 6.8x, while diversified surgical implant and device platforms sit at 2.2x. Installed-base pull-through and recurring procedure revenue offer a clearer path to compounding revenue. 4 Higher Pricing Sits with Both Growth and Margin Among 16 names with margin data, 3 clear both operating bars and sit at 4.0x. The 3 clearing neither sit at 1.6x, showing how uncommon balanced performance is in this set. 2.3x Sector median EV/Revenue CY2027E consensus · EV/Revenue is the lens because practitioners price this growth set on revenue and 6 of 27 names are… 6.6x Premium end EV/Revenue vs 1.0x at the discount end top quartile (n=7) against bottom quartile (n=5) on EV/Revenue — the spread the report explains 28 Transactions with disclosed terms 74 recorded in this tier · 3 told as case studies, the full list in the appendix

  4. 04
    SECTION 02

    02

    Section divider introducing the four operating models that compete for capital.

    Four operating models compete for capital in this sector, and they don't compete on the same terms. Revenue mix, channel maturity and recurring procedure economics are what separate them — that's what the next two pages lay out.

    Everything on this page

    SECTION 02 02 THE LANDSCAPE Four Operating Models Compete for Capital on Different Terms Revenue mix, channel maturity and recurring procedure economics shape relative standing. 02 of 06 Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 4

  5. 05
    02 · MARKET MAP

    Recurring Procedure Economics Sit at the Valuable End of the Map

    This page maps the approved company set by business segment, showing the market places the most value on recurring procedure economics.

    We've grouped the approved companies by business segment and plotted each group's median forward valuation. Instruments and procedural consumables businesses sit at the top of the map at 6.8x, while diversified implant and device platforms sit near the bottom at 2.2x. That gap tracks with recurring procedure economics rather than scale. So what: where a company's revenue sits on the recurring-versus-capital-equipment spectrum is a strong signal for where it prices.

    Everything on this page

    02 · MARKET MAP Recurring Procedure Economics Sit at the Valuable End of the Map 27 approved companies grouped by business segment · median EV / Revenue (CY2027E) per group · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Segment grouping follows the platform's classification; group medians on rated names only. "Why it matters" lines are NeuraCap views. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 5 DIVERSIFIED SURGICAL IMPLANT AND DEVICE PLATFORMS 21 cos median 2.2x SYK ZBH SNN GMED IART CNMD AXGN ESTA ATEC INSP BVS PRCT SIBN KIDS SSII OFIX CLPT TMCI ARAY LNSR MBOT Scale and case coverage matter, but mature portfolios must offset price pressure through mix, evidence and procedure breadth. SURGICAL INSTRUMENTS AND PROCEDURAL CONSUMABLES 3 cos median 6.8x ISRG PDEX UTMD Installed systems can support recurring pull-through, linking utilisation and procedure volume to revenue quality. SPECIALTY SURGICAL DEVICE FRANCHISES 2 cos median 2.4x SI APYX Focused procedure ownership can deepen surgeon adoption, while concentration leaves execution tied to a narrower franchise. DIGITAL SURGERY PLANNING AND ENABLING TECHNOLOGY 1 cos 2.8x · 1 rated CARL Planning tools can strengthen workflow integration and surgeon adoption, although the group contains one name.

  6. 06
    02 · LANDSCAPE

    Recurring Revenue and Procedure Ownership Separate the Four Models

    This page describes what each of the four segment models does and why recurring revenue and procedure ownership separate them.

    Each of the four operating models generates revenue differently — some sell capital equipment, others own the recurring procedure. We walk through what each model actually does commercially, not just how it prices. Understanding the mechanics behind the multiple is what lets you judge whether a company's current pricing is durable. So what: the label matters less than whether the business owns the procedure.

    Everything on this page

    02 · LANDSCAPE Recurring Revenue and Procedure Ownership Separate the Four Models Segment view of the approved universe · EV / Revenue (CY2027E) medians on rated names · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. "What they do / why it matters" is a NeuraCap view. Full company-level detail in the appendix and companion tables. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 6 Segment n Share of universe Median EV/Revenue Names to know What they do — and why it matters Diversified surgical implant and device platforms 21 78% 2.2x Stryker Corporation (SYK) · Zimmer Biomet Holdings, Inc. (ZBH) · +19 more Scale carries operating weight. These platforms combine implants, devices and established case coverage. Their standing depends on mix, set utilisation and the ability to protect pricing across mature franchises. Surgical instruments and procedural consumables 3 11% 6.8x Intuitive Surgical, Inc. (ISRG) · Pro-Dex, Inc. (PDEX) · +1 more Placements create recurring pull-through. Capital systems and instruments can support repeat consumable demand. Utilisation, attach rates and installed-base quality matter more than placement volume alone. Specialty surgical device franchises 2 7% 2.4x Shoulder Innovations, Inc. (SI) · Apyx Medical Corporation (APYX) Procedure focus sharpens adoption. Focused franchises can build surgeon champions and clear positioning. Their economics remain sensitive to reimbursement, channel depth and concentration. Digital surgery planning and enabling technology 1 4% 2.8x n=1 Carlsmed, Inc. (CARL) Workflow integration supports relevance. Digital planning can sit inside the surgical workflow and reinforce adoption. The segment contains one company, so its valuation should be read as company-specific.

  7. 07
    SECTION 03

    03

    Section divider introducing the premium end of the market, where faster growth meets durable procedure economics.

    The premium end of this sector combines faster growth with durable procedure economics. Forward revenue multiples separate sharply across the approved peer set — the next several pages show exactly how.

    Everything on this page

    SECTION 03 03 VALUATION & SITUATIONS The Premium End Combines Faster Growth with Durable Procedure Economics Forward revenue multiples separate sharply across the approved peer set. 03 of 06 Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 7

  8. 08
    03 · PUBLIC MARKET VALUATION

    Forward Revenue Pricing Separates Durable Growth from Execution Risk

    This page ranks the rated companies by forward EV/Revenue, showing a sector median of 2.3x and a wide spread across the set.

    We rank the rated companies by forward EV/Revenue, and the sector median lands at 2.3x. The range is wide: the premium end trades at 6.6x while the discount end sits at 1.0x. We use EV/Revenue rather than EV/EBITDA because that's how practitioners price this sector, and because a number of names are loss-making on forward EBITDA. So what: a 2.3x median hides a genuinely bifurcated market, and knowing where a name sits in that range tells you what the market believes about its durability.

    Everything on this page

    03 · PUBLIC MARKET VALUATION Forward Revenue Pricing Separates Durable Growth from Execution Risk EV / Revenue (CY2027E) · all 25 rated companies, sorted descending · sector median 2.3x · EV/Revenue is the lens because practitioners price this growth set on revenue and 6 of 27 names are loss-making on forward EBITDA · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Primary valuation basis: EV / Revenue on CY2027E consensus (25 of 27 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (26 of 27 companies), so this report follows it. Tier zones are NeuraCap groupings cut at the rated set's quartiles; every multiple quoted on this page is a median on the same EV / Revenue (CY2027E) basis. Panel commentary is a NeuraCap view. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 8 PREMIUM · median 6.6x CORE · median 2.2x DISCOUNT · median 1.0x Sector median 2.3x WHAT SEPARATES THE TWO ENDS The top sells durability. The premium end carries a 6.6x middle, while the discount end sits at 1.0x. The forward basis already credits forecast growth, making confidence in persistence central to the gap. Pull-through supports revenue quality. Installed-base productivity, recurring implants and consumables can make growth more repeatable. Placements without utilisation offer less support. Channel economics protect growth. Case coverage, GPO and IDN contracting, and disciplined consignment-set deployment can strengthen the economics behind reported revenue.

  9. 09
    03 · VALUATION DRIVERS

    Faster Growth Carries Higher Forward Revenue Pricing

    This page shows that companies growing revenue faster than the covered median price at a meaningfully higher forward multiple.

    We split the rated set at its covered median revenue growth: the faster-growing names price at a 2.8x median versus 2.1x for the slower-growing names. Margin cohorts show a similar directional pattern. This is an association we observe in the data, not a claim that growth causes the premium. So what: growth alone doesn't guarantee a premium multiple, but it correlates strongly with one in this sector.

    Everything on this page

    03 · VALUATION DRIVERS Faster Growth Carries Higher Forward Revenue Pricing Median EV / Revenue (CY2027E) by revenue-growth cohort and by EBITDA-margin cohort (each split at its covered median) · rated names with estimates · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Cohort medians on rated names with the required estimates (faster n=13; slower n=12; higher-margin n=8; lower-margin n=8). Driver readings are NeuraCap views on the supplied data — association, not causation. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 9 EV/Revenue, median per cohort · growth split at 11% · EBITDA-margin split at 21% Growth Above the Split Is Associated with Higher Pricing The 13 names above 11% carry a 2.8x middle, compared with 2.1x for the 12 names below 11%. Recurring Pull-Through Strengthens the Growth Case Procedure volume, utilisation and attach rates help distinguish productive installed bases from capital placements that have yet to generate recurring demand. Evidence and Access Help Defend Adoption Clinical support, reimbursement and contracted access can reinforce surgeon conversion and help a franchise hold its position as procedures migrate across sites of care.

  10. 10
    03 · SITUATION MAP

    The Market Separates Premium Growth from Growth Still Seeking Proof

    This page places each company into one of four situations, cut on the 2.3x sector median valuation and the 11% covered median growth rate.

    We cut the rated set on two axes: EV/Revenue against the 2.3x sector median, and revenue growth against the 11% covered median. That produces four situations rather than one undifferentiated peer group. These are observations about where each company currently sits, not recommendations. So what: two companies with similar headline growth can be in very different situations once you check where their valuation actually sits.

    Everything on this page

    03 · SITUATION MAP The Market Separates Premium Growth from Growth Still Seeking Proof Cut on EV / Revenue vs the sector median (2.3x) (rows) and revenue growth vs the covered median (11%) (columns) · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Situation boundaries are the cohort's own medians (Directional, NeuraCap view). This page characterises situations; it does not recommend buying or selling any security. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 10 Premium Growth Above-median multiple · above-median revenue growth 8 names Intuitive Surgical, Inc. (ISRG) · AxoGen, Inc. (AXGN) · Establishment Labs Holdings Inc. (ESTA) · +5 more Eight names sit above both the valuation and growth markers. Their agenda is to sustain procedure growth while protecting pull-through, channel economics and operating discipline. Premium Resilience Above-median multiple · below-median revenue growth 5 names Stryker Corporation (SYK) · Zimmer Biomet Holdings, Inc. (ZBH) · Globus Medical, Inc. (GMED) · +2 more Five names hold above-range pricing despite slower growth. Their position suggests durability or platform quality, while renewed procedure growth would strengthen the case. Growth Seeking Proof Below-median multiple · above-median revenue growth 5 names Alphatec Holdings, Inc. (ATEC) · PROCEPT BioRobotics Corporation (PRCT) · OrthoPediatrics Corp. (KIDS) · +2 more Five names grow faster while sitting below the valuation marker. The gap suggests that investors are still testing revenue quality, margin potential or the durability of adoption. Operational Reset Below-median multiple · below-median revenue growth 7 names Smith & Nephew plc (SNN) · Integra LifeSciences Holdings Corporation (IART) · CONMED Corporation (CNMD) · +4 more Seven names sit below both markers. The operating question is where portfolio focus, pricing, cost structure or capital allocation can improve relative standing.

  11. 11
    03 · GROWTH VS PROFITABILITY

    Balanced Growth and Margin Remain Uncommon in the Measured Set

    This page plots companies with both growth and margin estimates, cut at 6% growth and 21% margin, showing balanced performers are rare.

    Among the companies with both revenue growth and EBITDA margin estimates, we cut the set at 6% growth and 21% margin. Only the names clearing both bars carry a 4.0x median, while those clearing neither sit at 1.6x. Balanced growth-and-margin performance is the exception here, not the rule. So what: if a name can demonstrate it clears both bars, that scarcity itself is part of the valuation case.

    Everything on this page

    03 · GROWTH VS PROFITABILITY Balanced Growth and Margin Remain Uncommon in the Measured Set Revenue growth (CY2027E, x-axis) vs EBITDA margin (CY2027E, y-axis) · 16 companies with both estimates · cuts at the covered medians (6% growth, 21% margin) · median EV/Revenue per quadrant · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. Quadrant cuts are the covered set's medians. Quadrant medians on names with a meaningful EV/Revenue (balanced n=3; margin-only n=5; growth-only n=5; neither n=3). Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 11 5% 10% 15% 20% 25% 10% 20% 30% 40% MARGIN ONLY median 2.2x BALANCED median 4.0x NEITHER median 1.6x GROWTH ONLY median 2.7x OFIX IART ZBH INSP PDEX CNMD SNN GMED BVS SYK KIDS ISRG ATEC SIBN AXGN ESTA x: revenue growth (CY2027E) · y: EBITDA margin (CY2027E) HOW TO READ THIS The chart compares growth with margin across the 16 names carrying both measures. Only 3 of 16 clear both bars, and they sit at 4.0x. The 3 of 16 clearing neither sit at 1.6x. The remaining names clear one bar, showing that many businesses are still trading between expansion and operating leverage. The balanced median rests on 3 names and is lifted by ISRG at 10.7x. Rule of 40 (revenue growth + EBITDA margin ≥ 40%): 3 of 16 names clear it (ISRG, ESTA, GMED).

  12. 12
    03 · THE AGENDA

    Choose the Operating Path That Strengthens Relative Standing

    This page frames the operating questions an owner or acquirer should resolve to strengthen relative standing.

    Based on everything in this analysis, we see three practical paths: deepen recurring procedure revenue, broaden procedure ownership selectively, or protect growth through tighter operating leverage. These are framed as questions to resolve, not prescriptions — the right path depends on where a business already sits on the map. So what: the operating agenda should follow from the situation, not the other way around.

    Everything on this page

    03 · THE AGENDA Choose the Operating Path That Strengthens Relative Standing NeuraCap view · framed as the questions an owner or acquirer should resolve · observations, not recommendations Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All content on this page is Directional — NeuraCap advisory judgment grounded in the cohort data shown earlier. It does not constitute investment advice. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 12 Deepen Recurring Procedure Revenue Prioritise utilisation, implant and consumable pull-through, and surgeon conversion across the installed base. What changes the answer: The answer changes when placements are not translating into repeat procedure revenue. Broaden Procedure Ownership Selectively Test adjacent products and build-versus-buy choices against channel fit, case coverage and contracted customer access. What changes the answer: The answer changes when an adjacent franchise can use the existing sales force without adding disproportionate set and inventory cost. Protect Growth Through Operating Leverage Align field investment, consignment sets and trunk stock with procedure demand rather than placement ambition alone. What changes the answer: The answer changes when working capital and case-coverage costs rise faster than productive utilisation.

  13. 13
    SECTION 04

    04

    Section divider introducing precedent transactions in surgical and orthopedic devices.

    Strategic buyers keep adding procedure breadth and channel reach through M&A. The precedent transactions we cover next span platform combinations, adjacent franchises and enabling technology.

    Everything on this page

    SECTION 04 04 PRECEDENT TRANSACTIONS Strategic Buyers Keep Adding Procedure Breadth and Channel Reach Precedent transactions span platform combinations, adjacent franchises and enabling technology. 04 of 06 Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 13

  14. 14
    04 · DEAL CASE STUDIES

    Precedent Transactions Favour Procedure Breadth and Channel Fit

    This page walks through select disclosed-terms precedent transactions as case studies, told on an LTM-at-announcement basis.

    We walk through a handful of precedent transactions with disclosed terms as detailed case studies, with multiples on LTM financials at announcement. These deal multiples sit on a different basis than our forward public-market figures, so we don't claim a spread between them. What we can say is what the deals themselves reveal about buyer priorities. So what: the pattern across these case studies is buyers paying for procedure breadth and channel fit, not just scale.

    Everything on this page

    04 · DEAL CASE STUDIES Precedent Transactions Favour Procedure Breadth and Channel Fit 3 of 28 transactions with disclosed terms, told as case studies · multiples on LTM financials at announcement where disclosed · the complete list is in the appendix · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. "Why the deal happened" is a NeuraCap read of the recorded evidence. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 14 Feb-2023 $4.1B Globus Medical, Inc. acquires NuVasive, Inc. EV / LTM revenue 3.4x EV / LTM EBITDA 13.4x WHY THE DEAL HAPPENED The pairing of two spine businesses suggests a strategy built around broader case coverage, enabling technology and a larger commercial footprint. The completed status indicates the combination moved beyond announcement. HOW THE TARGET WAS VALUED The transaction carried $4.1B of value, with 3.4x revenue and 13.4x EBITDA. The revenue multiple stood above the 2.3x middle of the public peer set. Jan-2025 $1.0B Zimmer Biomet Holdings, Inc. acquires Paragon 28, Inc. EV / LTM revenue 4.1x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests that a focused extremities portfolio can benefit from a broader orthopedic channel, contracted access and case coverage. The announced structure points to strategic interest in adjacent procedure ownership. HOW THE TARGET WAS VALUED The transaction carried $1.0B of value at 4.1x revenue. That level stood above the middle of the public peer range. Oct-2022 $849M Orthofix Medical Inc. acquires SeaSpine Holdings Corporation EV / LTM revenue 3.7x EV / LTM EBITDA n/a WHY THE DEAL HAPPENED The transaction suggests value in combining complementary portfolios, surgeon relationships and commercial reach. It also fits the pattern of specialists adding adjacent capabilities to complete a procedure offering. HOW THE TARGET WAS VALUED The transaction carried $849M of value at 3.7x revenue. That level also stood above the middle of the public peer range.

  15. 15
    SECTION 05

    05

    Section divider introducing the operating agenda to deepen pull-through and protect growth quality.

    The operating agenda here is to deepen pull-through and protect growth quality. Installed-base productivity, procedure ownership and channel economics are the practical levers we cover next.

    Everything on this page

    SECTION 05 05 STRATEGIC IMPLICATIONS The Operating Agenda Is to Deepen Pull-Through and Protect Growth Quality Installed-base productivity, procedure ownership and channel economics are the practical levers. 05 of 06 Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 15

  16. 16
    05 · STRATEGIC IMPLICATIONS

    Value Strengthens When Growth Converts into Repeatable Procedure Economics

    This page sets out NeuraCap's view that value strengthens when growth converts into repeatable procedure economics.

    Our view is that value strengthens when growth converts into repeatable procedure economics rather than one-off placements. That means tracking whether installed-base investment is actually generating repeat procedure revenue, matching cost structure to channel productivity, and tying capital allocation to procedure ownership. These are the questions we think matter most over the next twelve months. So what: the operating test isn't whether you placed the system — it's whether the system keeps getting used.

    Everything on this page

    05 · STRATEGIC IMPLICATIONS Value Strengthens When Growth Converts into Repeatable Procedure Economics NeuraCap view · the questions this data puts on the table for the next twelve months Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. This page is Directional — NeuraCap views drawn from the analysis in this report. Observations, not recommendations. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 16 FOR OWNERS Make Installed-Base Quality the Operating Test Track whether systems, sets and surgeon adoption convert into repeat procedures and recurring pull-through. Capital placement without sustained utilisation leaves the growth case exposed. FOR MANAGEMENT TEAMS Match the Cost Base to Channel Productivity Focus field coverage, inventory and consignment investment on territories and procedures where utilisation can support durable economics. FOR BOARDS Tie Capital Allocation to Procedure Ownership Assess organic investment and build-versus-buy choices through procedure breadth, channel fit, reimbursement support and the ability to deepen recurring revenue.

  17. 17
    SECTION 06

    06

    Section divider introducing the full comparables universe, methodology and sources.

    The final section carries the full universe, the methodology and the sources behind every figure in this report. It's there for anyone who wants to trace a number back to its disclosure.

    Everything on this page

    SECTION 06 06 APPENDIX The Full Universe, Methodology and Sources Comparables detail behind every figure in the body, the valuation basis, and where each underlying disclosure lives. 06 of 06 Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 17

  18. 18
    06 · PUBLIC COMPARABLES (1 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This appendix page lists public comparables on forward EV/Revenue, grouped by valuation tier against the 2.3x sector median.

    This page lists the public comparables behind every multiple in this report, shaded against the 2.3x sector median. Each rated company carries a forward EV/Revenue multiple, and every ticker links back to its underlying source. So what: this is where you go to check any multiple we've quoted against its own disclosure.

    Everything on this page

    06 · PUBLIC COMPARABLES (1 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.3x); amber marks below · 25 rated companies; 2 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 25 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 18 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 PREMIUM — ≥3.1x · median 6.6x · 7 companies Intuitive Surgical, Inc. ISRG Surgical instruments and procedural consumables $143B 10.7x 13% 44% 57 ClearPoint Neuro, Inc. CLPT Diversified surgical implant and device platforms $487M 8.6x 15% n/a n/a SS Innovations International, Inc. SSII Diversified surgical implant and device platforms $576M 7.6x 28% n/a n/a AxoGen, Inc. AXGN Diversified surgical implant and device platforms $2.2B 6.6x 20% 12% 32 Establishment Labs Holdings Inc. ESTA Diversified surgical implant and device platforms $2.1B 6.2x 26% 16% 41 Stryker Corporation SYK Diversified surgical implant and device platforms $117B 4.0x 9% 29% 38 Shoulder Innovations, Inc. SI Specialty surgical device franchises $278M 3.2x 29% n/a n/a CORE — 1.7x–3.1x · median 2.2x · 13 companies Globus Medical, Inc. GMED Diversified surgical implant and device platforms $9.6B 2.8x 6% 35% 41 Pro-Dex, Inc. PDEX Surgical instruments and procedural consumables $241M 2.8x 4% 19% 24 Carlsmed, Inc. CARL Digital surgery planning and enabling technology $306M 2.8x 41% n/a n/a Zimmer Biomet Holdings, Inc. ZBH Diversified surgical implant and device platforms $24.8B 2.8x 4% 33% 37 SI-BONE, Inc. SIBN Diversified surgical implant and device platforms $727M 2.7x 16% 7% 23 Bioventus Inc. BVS Diversified surgical implant and device platforms $1.5B 2.3x 7% 21% 28 Smith & Nephew plc SNN Diversified surgical implant and device platforms $15.0B 2.2x 5% 23% 28 OrthoPediatrics Corp. KIDS Diversified surgical implant and device platforms $634M 2.1x 12% 11% 23

  19. 19
    06 · PUBLIC COMPARABLES (2 OF 2)

    Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier

    This is the second page of the public comparables appendix, continuing the same valuation-tier grouping.

    This continues the comparables table, covering the remainder of the rated companies against the same 2.3x sector median shading. The full field set for every name sits in the companion workbook. So what: nothing here is summarized — it's the complete rated set, available for your own diligence.

    Everything on this page

    06 · PUBLIC COMPARABLES (2 OF 2) Public Comparables on EV / Revenue (CY2027E), Grouped by Valuation Tier Teal shading marks a EV/Revenue above the sector median (2.3x); amber marks below · 25 rated companies; 2 not rated (no eligible EV/Revenue) · tickers link to the underlying source · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. All 25 rated rows are in this appendix and in the companion workbook, which carries the complete field set. Names without an eligible multiple are listed in the companion workbook. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 19 Company Ticker Segment EV EV/Revenue (CY2027E) Rev growth EBITDA margin Rule of 40 CORE — CONTINUED — 1.7x–3.1x · median 2.2x · 13 companies Alphatec Holdings, Inc. ATEC Diversified surgical implant and device platforms $2.0B 2.0x 15% 18% 33 Inspire Medical Systems, Inc. INSP Diversified surgical implant and device platforms $1.8B 2.0x 4% 22% 26 Integra LifeSciences Holdings Corporation IART Diversified surgical implant and device platforms $3.0B 1.8x 3% 22% 25 Apyx Medical Corporation APYX Specialty surgical device franchises $113M 1.7x 11% n/a n/a PROCEPT BioRobotics Corporation PRCT Diversified surgical implant and device platforms $814M 1.7x 21% n/a n/a DISCOUNT — <1.7x · median 1.0x · 5 companies CONMED Corporation CNMD Diversified surgical implant and device platforms $2.2B 1.6x 5% 20% 25 Treace Medical Concepts, Inc. TMCI Diversified surgical implant and device platforms $310M 1.4x 7% n/a n/a LENSAR Inc LNSR Diversified surgical implant and device platforms $72M 1.0x 21% n/a n/a Orthofix Medical Inc. OFIX Diversified surgical implant and device platforms $539M 0.6x 2% 12% 14 Accuray Incorporated ARAY Diversified surgical implant and device platforms $151M 0.3x 3% n/a n/a

  20. 20
    06 · PRECEDENT TRANSACTIONS (1 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This appendix page lists precedent transactions with disclosed terms, newest first.

    This page lists precedent transactions with disclosed terms, newest first. Multiples are on LTM financials at announcement, and deal values link back to the underlying filing. So what: this is the primary evidence base behind the deal patterns we describe earlier in the report.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (1 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 28 transactions with disclosed terms in this tier (74 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 28 transactions shown; the rest are in the companion workbook. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 20 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Mar-2025 Alcon Research, LLC → Lensar, Inc. $148M 2.8x n/a The transaction paired an established eye-care buyer with a surgical technology platform, suggesting strategic interest in workflow and procedure expansion. Jan-2025 Zimmer Biomet Holdings, Inc. → Paragon 28, Inc. $1.0B 4.1x n/a The transaction suggests value in placing an adjacent orthopedic franchise into a broader commercial channel and contracted customer base. Aug-2023 STERIS plc → Surgical Instrumentation platform $540M n/a n/a The transaction points to strategic demand for instruments that can deepen procedure coverage and recurring customer relationships. Feb-2023 Globus Medical, Inc. → NuVasive, Inc. $4.1B 3.4x 13.4x The completed transaction combined spine platforms, suggesting value in broader procedure coverage, enabling technology and sales-force reach. Feb-2023 Boston Scientific Corporation → Apollo Endosurgery, Inc. $407M 5.3x n/a The transaction suggests strategic interest in adding a focused procedure franchise to an established medical-device channel. Oct-2022 Orthofix Medical Inc. → SeaSpine Holdings Corporation $849M 3.7x n/a The transaction indicates that complementary portfolios and broader case coverage can support consolidation among specialist platforms. Jul-2021 Bioventus Inc. → Bioness Inc. and Misonix Inc. $61M 7.0x n/a The transaction suggests interest in combining focused technologies with a broader commercial platform and customer base. Jun-2021 D8 Holdings Corp. → Vicarious Surgical Inc. $1.0B n/a n/a The pending transaction points to investor interest in surgical robotics during the clinical-evidence and placement phase. Nov-2020 Stryker Corporation → Wright Medical Group N.V. n/a 5.8x n/a The transaction suggests that a focused implant franchise can gain value inside an established case-covering channel.

  21. 21
    06 · PRECEDENT TRANSACTIONS (2 OF 2)

    All Precedent Transactions with Disclosed Terms, Newest First

    This is the second page of the precedent transactions appendix, continuing the same disclosed-terms list.

    This continues the precedent transaction list, completing the disclosed-terms deals shown in this report. The remaining recorded transactions sit in the companion workbook for further review. So what: this table is the full evidentiary record behind the M&A commentary in section four.

    Everything on this page

    06 · PRECEDENT TRANSACTIONS (2 OF 2) All Precedent Transactions with Disclosed Terms, Newest First 28 transactions with disclosed terms in this tier (74 recorded) · multiples on LTM financials at announcement where disclosed · deal values link to the underlying filing · as of 2026-09-28 Source: NeuraCap analytics platform; market data and consensus estimates as of 2026-09-28; company disclosures via SEC EDGAR where linked. 122 precedent record(s) carry data-quality flags (deal value unit unresolved; divestiture roles reassigned; duplicate filings collapsed); figures are shown as recorded in the filing. 46 recorded transactions with neither a disclosed value nor a multiple are omitted from the precedent list and the case studies (kept in the companion workbook). Deal multiples are LTM at announcement (Definitive, from filings); they are not directly comparable to the CY2027E public basis and no spread is claimed. 18 of 28 transactions shown; the rest are in the companion workbook. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 21 Date Transaction EV EV/LTM Rev EV/LTM EBITDA Why it matters Jul-2020 Medtronic plc → Medicrea International n/a 7.6x n/a Feb-2020 Anika Therapeutics, Inc. → ArthroSurface Incorporated n/a 3.4x n/a May-2019 Boston Scientific Corporation → Vertiflex, Inc. n/a 18.0x 6.5x May-2019 Medtronic plc → Titan Spine, Inc. n/a 4.0x n/a Dec-2018 Patterson Companies → RTI Surgical, Inc. n/a 16.2x 16.2x Value shown as recorded in the filing; deal value unit unresolved. Nov-2018 Colfax Corporation → DJO Global, Inc. n/a n/a 11.7x Sep-2018 Medtronic plc → Mazor Robotics Ltd. n/a 25.2x 18.6x Aug-2018 Stryker Corporation → K2M Group Holdings, Inc. n/a 4.9x n/a Value shown as recorded in the filing; deal value unit unresolved. Aug-2018 Wright Medical Group, Inc. → Cartiva, Inc. n/a 18.0x n/a

  22. 22
    06 · METHODOLOGY

    Sources, Assumptions and Data Quality

    This page explains the sources, assumptions and data-quality treatment behind the report.

    Every figure in this report links to the record it was taken from, and where it doesn't, the appendix names the source and the basis on which it was read. We've also documented what was excluded and why. So what: this page is your reference for standing behind any number in this deck with a client.

    Everything on this page

    06 · METHODOLOGY Sources, Assumptions and Data Quality How this report was built, what was excluded, and where every underlying disclosure lives · as of 2026-09-28 Every figure in this report links to the record it was taken from. Where a figure has no link, the appendix names its source and the basis on which it was read. Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice 22 VALUATION BASIS Primary valuation basis: EV / Revenue on CY2027E consensus (25 of 27 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (26 of 27 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Surgical and Orthopedic Devices and it clears the coverage gate with 25 of 27 companies (93%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (16 of 27 names with a meaningful EBITDA). DATA QUALITY & EXCLUSIONS 81 records were excluded or quarantined by the platform's validation gates (unit errors, implausible ratios, ineligible securities and classification failures); the full ledger ships in the companion tables and never feeds a statistic in this report. DEFINITIVE VS DIRECTIONAL Definitive content is disclosed or consensus data passed through stated arithmetic. Directional content — tier boundaries, situation cuts, "why it matters" commentary, the agenda pages — is NeuraCap analyst judgment and is labeled as such where it appears. WHAT THIS REPORT IS NOT This report characterises a sector. It does not recommend buying, selling or holding any security, and no statement in it should be read as investment advice or a price target. WHERE THE DATA LIVES 1077 registered source documents stand behind the figures in this report. Metric hyperlinks throughout the deck open the specific filing or data record; by publisher: sec.gov (1076) · home.treasury.gov (1). The companion workbook beside this deck carries the complete source index.

  23. 23

    Higher Pricing Sits with Durable Growth, Recurring Pull-Through and Procedure Breadth.

    Closing slide restating that higher pricing sits with durable growth, recurring pull-through and procedure breadth.

    Higher pricing in this sector sits with durable growth, recurring pull-through and procedure breadth. The companion tables carry the full universe and source index for any figure you want to trace further with your team.

    Everything on this page

    Higher Pricing Sits with Durable Growth, Recurring Pull-Through and Procedure Breadth. NeuraCap AI — Surgical and Orthopedic Devices Coverage September 2026 · Prepared by NeuraCap AI · Confidential Surgical and Orthopedic Devices Coverage | September 2026 | Confidential | Not investment advice Sources & methodology 23

Sources and methodology

This report covers Surgical and Orthopedic Devices (Health Care › Health Care Equipment and Services › Surgical and Orthopedic Devices) with market data and consensus estimates as of September 28, 2026. The company universe is the 27 listed companies whose core business is Surgical and Orthopedic Devices according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Apyx Medical Corporation (APYX), Accuray Incorporated (ARAY), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Bioventus Inc. (BVS), Carlsmed, Inc. (CARL), ClearPoint Neuro, Inc. (CLPT), CONMED Corporation (CNMD), Establishment Labs Holdings Inc. (ESTA), Globus Medical, Inc. (GMED), Integra LifeSciences Holdings Corporation (IART), Inspire Medical Systems, Inc. (INSP), Intuitive Surgical, Inc. (ISRG), OrthoPediatrics Corp. (KIDS), LENSAR Inc (LNSR), Microbot Medical Inc. (MBOT), Orthofix Medical Inc. (OFIX), Pro-Dex, Inc. (PDEX), PROCEPT BioRobotics Corporation (PRCT), Shoulder Innovations, Inc. (SI), SI-BONE, Inc. (SIBN), Smith & Nephew plc (SNN), SS Innovations International, Inc. (SSII), Stryker Corporation (SYK), Treace Medical Concepts, Inc. (TMCI), Utah Medical Products, Inc. (UTMD), Zimmer Biomet Holdings, Inc. (ZBH). The market map groups them by business vertical — Diversified surgical implant and device platforms: 21 companies (SYK, ZBH, SNN, GMED, IART, CNMD, AXGN, ESTA, ATEC, INSP, BVS, PRCT, SIBN, KIDS, SSII, OFIX, CLPT, TMCI, ARAY, LNSR, MBOT); Surgical instruments and procedural consumables: 3 companies (ISRG, PDEX, UTMD); Specialty surgical device franchises: 2 companies (SI, APYX); Digital surgery planning and enabling technology: 1 company (CARL). 25 of the 27 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

Scope and company universe

This report covers Surgical and Orthopedic Devices (Health Care › Health Care Equipment and Services › Surgical and Orthopedic Devices) with market data and consensus estimates as of September 28, 2026. The company universe is the 27 listed companies whose core business is Surgical and Orthopedic Devices according to NeuraCap's industry classification of each company's reported business segments (a company is included only when this industry is central to what it does, not merely adjacent to it). Companies in the set: Apyx Medical Corporation (APYX), Accuray Incorporated (ARAY), Alphatec Holdings, Inc. (ATEC), AxoGen, Inc. (AXGN), Bioventus Inc. (BVS), Carlsmed, Inc. (CARL), ClearPoint Neuro, Inc. (CLPT), CONMED Corporation (CNMD), Establishment Labs Holdings Inc. (ESTA), Globus Medical, Inc. (GMED), Integra LifeSciences Holdings Corporation (IART), Inspire Medical Systems, Inc. (INSP), Intuitive Surgical, Inc. (ISRG), OrthoPediatrics Corp. (KIDS), LENSAR Inc (LNSR), Microbot Medical Inc. (MBOT), Orthofix Medical Inc. (OFIX), Pro-Dex, Inc. (PDEX), PROCEPT BioRobotics Corporation (PRCT), Shoulder Innovations, Inc. (SI), SI-BONE, Inc. (SIBN), Smith & Nephew plc (SNN), SS Innovations International, Inc. (SSII), Stryker Corporation (SYK), Treace Medical Concepts, Inc. (TMCI), Utah Medical Products, Inc. (UTMD), Zimmer Biomet Holdings, Inc. (ZBH). The market map groups them by business vertical — Diversified surgical implant and device platforms: 21 companies (SYK, ZBH, SNN, GMED, IART, CNMD, AXGN, ESTA, ATEC, INSP, BVS, PRCT, SIBN, KIDS, SSII, OFIX, CLPT, TMCI, ARAY, LNSR, MBOT); Surgical instruments and procedural consumables: 3 companies (ISRG, PDEX, UTMD); Specialty surgical device franchises: 2 companies (SI, APYX); Digital surgery planning and enabling technology: 1 company (CARL). 25 of the 27 companies carry a valid multiple on the primary valuation basis and form the rated set behind every cohort statistic; the others are shown but do not enter the statistics.

What was excluded and why

81 records failed a validation gate and never feed a statistic in this report (79 excluded from aggregate; 2 quarantined). Each exclusion, with its reason: APYX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · APYX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · APYX — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · APYX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · APYX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · APYX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · APYX — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARAY — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · ARAY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARAY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ARAY — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · ATEC — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · AXGN — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CARL — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLPT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CLPT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CLPT — EBITDA is non-positive; EV/EBITDA is n/m (effect: excluded from aggregate) · CLPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · CLPT — Non-positive EPS; P/E is n/m (effect: excluded from aggregate) · further items are listed in the companion tables.

Primary valuation basis and how it was chosen

Primary valuation basis: EV / Revenue on CY2027E consensus (25 of 27 companies eligible; multiples failing the platform's plausibility gates are excluded, never plotted). Practitioners price this industry on EV / Revenue rather than EV / EBITDA; validated coverage supports the industry standard (26 of 27 companies), so this report follows it. EV / Revenue on CY2027E is the lead convention: it is the sector-appropriate prior for Surgical and Orthopedic Devices and it clears the coverage gate with 25 of 27 companies (93%). P / E is carried as a cross-check. A revenue lens is used rather than a profit multiple because the set is not consistently profitable on a forward basis (16 of 27 names with a meaningful EBITDA). The basis is selected in two steps: the industry's customary valuation conventions set the order of preference, and each convention is then tested for coverage — the share of companies with a valid, plausibility-checked multiple on the chosen period. A convention is used only when enough companies carry it; the best-covered convention is used, and disclosed, when none clears the threshold. Coverage measured for this report — EV / EBITDA: 16 of 27 companies; EV / rEVenue: 25 of 27 companies; P/E: 13 of 27 companies. 6 companies show a non-meaningful EV / EBITDA denominator and are excluded from that statistic. 12 companies show a non-meaningful P / E denominator and are excluded from that statistic.

How the multiples and statistics are computed

Enterprise value (EV) is market capitalisation at the as-of date plus total debt minus cash and equivalents from the latest reported balance sheet, reconciled against the platform's stored value and disclosed where the two differ. Forward multiples divide EV (or the share price for P/E) by the consensus estimate for the stated calendar period; trailing multiples use the last twelve months of reported figures from SEC filings. A multiple with a negative or immaterial denominator is treated as not meaningful and excluded from every statistic. Cohort statistics are medians and quartiles over the rated set only; a group median with fewer than three observations is shown as the single company's figure and labelled as such. Valuation tiers cut the rated set at its quartiles (tiers cut at the rated set's quartiles: Premium ≥3.1x, Core 1.7x–3.1x, Discount <1.7x — NeuraCap groupings). Revenue growth compares consecutive calendar-year consensus revenue; EBITDA margin divides consensus EBITDA by consensus revenue for the same period. Figures shown in this report and the calculation behind each: 2.3x = median(ev_revenue CY2027E) (25 rated companies) · 6.6x = median(ev_revenue CY2027E) within Premium tier (n=7) · 2.2x = median(ev_revenue CY2027E) within Core tier (n=13) · 1.0x = median(ev_revenue CY2027E) within Discount tier (n=5) · 2.8x = median(ev_revenue CY2027E) | growth ≥ 11% (n=13) · 2.1x = median(ev_revenue CY2027E) | growth < 11% (n=12) · 2.5x = median(ev_revenue CY2027E) | EBITDA margin ≥ 21% (n=8) · 2.4x = median(ev_revenue CY2027E) | EBITDA margin < 21% (n=8) · 28% = median Rule of 40 score (revenue growth + EBITDA margin) (n=16) · 4.0x = median(ev_revenue CY2027E) within balanced quadrant (n=3) · 2.2x = median(ev_revenue CY2027E) within marginOnly quadrant (n=5) · 2.7x = median(ev_revenue CY2027E) within growthOnly quadrant (n=5) · 1.6x = median(ev_revenue CY2027E) within neither quadrant (n=3) · 10.7x = ev_revenue CY2027E for ISRG (quadrant outlier)

Precedent transactions: what is in the record and why

The precedent record holds the M&A transactions in Surgical and Orthopedic Devices recorded from SEC filings (8-K announcements and the documents they reference), newest first, with each value and multiple linked to the exact passage in the filing that states it. 74 transactions were recorded for this industry; 28 are shown. 46 recorded transactions with neither a disclosed value nor a multiple are omitted because they say nothing about price; they remain in the companion workbook. Deal multiples are enterprise value over the target's last-twelve-month revenue or EBITDA at announcement, as disclosed; they are not restated to the public basis and no spread to the public multiples is claimed. Before a transaction reaches the record it passes a screen for mirrored or duplicate filings of the same deal, for divestitures where the filer is the seller rather than the buyer, for carve-outs recorded under the parent's name, and for values whose citation describes something other than the price paid (a debt raise, a termination fee); such records are corrected or excluded and the correction is noted. Data-quality notes on this record: 44 × deal value unit unresolved; 58 × no evidence record; 13 × duplicate precedent id; 1 × duplicate filings collapsed; 6 × divestiture roles reassigned. Case studies lead with the 3 richest stories — disclosed value, a readable multiple, newest first.

Sources

Company financials and transaction terms come from the companies' own SEC filings on EDGAR (10-K, 10-Q and 8-K documents), linked from each figure in the report. Forward figures are analyst consensus estimates for the calendar periods shown. Share prices and market capitalisations are market data as of September 28, 2026. Treasury yields are published by the U.S. Department of the Treasury. 1081 source documents stand behind this report; by publisher domain: sec.gov (1076), home.treasury.gov (1). Every figure on every page is traceable to one of these records; nothing in the report is derived from outside data.

Interpretation and important notice

Tier labels, situation maps, the agenda and the implications pages are NeuraCap analytical views drawn from the recorded evidence and are labelled as such. The report is informational: it is not investment advice, not a recommendation to buy or sell any security, not an opinion of value and not an offer of any kind. Readers should perform their own diligence before acting on anything described here.

Sources linked in the report

This report is published for information only. It is not a recommendation to buy or sell any security, an offer or solicitation, an appraisal or a fairness opinion, and no fiduciary relationship is created by reading it. Multiples that fail NeuraCap’s plausibility gates are excluded and never plotted. See the full methodology and the disclaimer.

Want this analysis for a company in Surgical and Orthopedic Devices?

Company valuation reports run the same method against a single business — public or private.